Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference

Krakow, Poland – January 3, 2022 – Ryvu Therapeutics (WSE:RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that it will participate in the following upcoming virtual investor conferences:


  • H.C. Wainwright Bioconnect Virtual Conference, taking place January 10-13, 2022;
    Ryvu’s pre-recorded corporate presentation will be available on-demand on the event platform, starting January 10, 7:00 AM (ET). Ryvu’s Management Board will also host investor meetings during the conference.